Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel in previously treated squamous lung cancer
NCT01969955Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2013
- Primary completion
- Dec 2014
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in squamous cell carcinoma of the lung (SCCL), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01969955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969955.